HC Wainwright Increases Earnings Estimates for Scholar Rock

Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) - Stock analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of Scholar Rock in a note issued to investors on Thursday, May 15th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.69) per share for the quarter, up from their previous estimate of ($0.72). The consensus estimate for Scholar Rock's current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Scholar Rock's Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($2.73) EPS, FY2026 earnings at ($1.96) EPS, FY2027 earnings at ($1.15) EPS and FY2028 earnings at ($0.12) EPS.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter in the prior year, the firm earned ($0.59) earnings per share.

Separately, Wedbush restated an "outperform" rating and issued a $50.00 price target on shares of Scholar Rock in a report on Wednesday, May 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Scholar Rock has an average rating of "Buy" and an average target price of $42.67.

Scholar Rock Stock Down 2.6%

Shares of SRRK stock traded down $0.82 during trading hours on Monday, reaching $30.72. The company had a trading volume of 891,869 shares, compared to its average volume of 1,268,117. The company has a market capitalization of $2.92 billion, a P/E ratio of -13.07 and a beta of 0.37. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $46.98. The stock's fifty day simple moving average is $31.01 and its 200 day simple moving average is $35.94.

Insider Activity

In other Scholar Rock news, Director Katie Peng sold 1,006 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the transaction, the director now directly owns 30,319 shares of the company's stock, valued at $1,043,579.98. This represents a 3.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Edward H. Myles sold 142,292 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $35.62, for a total value of $5,068,441.04. Following the transaction, the chief financial officer now owns 111,345 shares of the company's stock, valued at approximately $3,966,108.90. This trade represents a 56.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 154,798 shares of company stock worth $5,482,238 over the last ninety days. Corporate insiders own 13.30% of the company's stock.

Institutional Trading of Scholar Rock

A number of hedge funds and other institutional investors have recently made changes to their positions in SRRK. FMR LLC boosted its stake in Scholar Rock by 33.7% during the 4th quarter. FMR LLC now owns 13,635,261 shares of the company's stock valued at $589,316,000 after acquiring an additional 3,439,215 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Scholar Rock by 7.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,283,421 shares of the company's stock worth $401,231,000 after purchasing an additional 629,315 shares during the last quarter. Vanguard Group Inc. grew its stake in Scholar Rock by 2.1% in the first quarter. Vanguard Group Inc. now owns 4,845,205 shares of the company's stock worth $155,773,000 after purchasing an additional 101,723 shares in the last quarter. Marshall Wace LLP grew its stake in Scholar Rock by 1,283.7% in the fourth quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock worth $127,301,000 after purchasing an additional 2,732,546 shares in the last quarter. Finally, Bellevue Group AG increased its holdings in Scholar Rock by 16.2% in the fourth quarter. Bellevue Group AG now owns 2,510,690 shares of the company's stock valued at $108,512,000 after buying an additional 349,487 shares during the last quarter. Institutional investors own 91.08% of the company's stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.